Folic Acid Functionalized Diallyl Trisulfide–Solid Lipid Nanoparticles for Targeting Triple Negative Breast Cancer

DATS (diallyl trisulfide), an anti-oxidant and cytotoxic chemical derived from the plant garlic, has been found to have potential therapeutic activity against triple-negative breast cancer (TNBC). Its hydrophobicity, short half-life, lack of target selectivity, and limited bioavailability at the tumor site limit its efficacy in treating TNBC. Overexpression of the Folate receptor on the surface of TNBC is a well-known target receptor for overcoming off-targeting, and lipid nanoparticles solve the limitations of limited bioavailability and short half-life. In order to overcome these constraints, we developed folic acid (FA)-conjugated DATS-SLNs in this research. The design of experiment (DoE) method was employed to optimize the FA-DATS-SLNs’ nanoformulation, which resulted in a particle size of 168.2 ± 3.78 nm and a DATS entrapment of 71.91 ± 6.27%. The similarity index between MCF-7 and MDA-MB-231 cell lines demonstrates that FA-DATS-SLNs are more therapeutically efficacious in the treatment of aggravating TNBC. Higher cellular internalization and efficient Bcl2 protein downregulation support the hypothesis that functionalization of the FA on the surface of DATS-SLNs improves anticancer efficacy when compared with DATS and DATS-SLNs. FA-functionalized DATS-SLNs have demonstrated to be a promising therapeutic strategy for TNBC management.


Introduction
Breast cancer (BC) is one of the most common invasive tumors among women globally and is one of the prime causes of malignancy-related death. Men account for less than 1% of all diagnosed BC cases [1][2][3]. As per the latest GLOBOCAN data, BC will rise by 41% in incidence and by 59% in mortality if remained unchecked in the next 20 years. Currently, the highest mortality is seen in developing countries such as Barbados and Fiji whereas, in incidence, European countries such as Belgium and the Netherlands top the chart. BC is an etiologically and clinically complex disorder. With the development of screening mammography and effective therapy over the last few decades, the rate of survival has improved. However, overall success is still far away due to the heterogenic nature of the BC, drug resistance, and lack of novel targeted biomarkers.
The term "triple-negative breast cancer" (TNBC) refers to a kind of BC in which the Human Epidermal Growth Factor Receptor 2 (HER-2), Progesterone Receptor (PR),

Lipids Selection for FA-DATS-SLNs Formulation
The capacity of SLNs to encapsulate a certain drug is significantly influenced by the drug's solubilizing capacity within the solid lipid core, as the larger the solubilizing capacity, the greater the drug loading potential. A total of six solid lipids were used in the solubilizing capacity investigation, with palmitic acid having the highest solubilizing capacity compared with the other lipids ( Figure 1A). Palmitic acid had the highest drug solubilizing capability of 117.5 ± 10 mg/gm of lipid, whereas cetyl palmitate had the second highest at 68.3 ± 5 mg/gm of lipid. Triglycerides have numerous benefits as the backbone of lipid-based delivery systems. They are regularly taken in food, are totally digested and absorbed, and hence pose no health risks [15]. Palmitic acid has also been reported to be utilized in the manufacture of SLNs throughout recent research [16].

Surfactant Selection for FA-DATS-SLNs Formulation
SLNs are colloidal nanoparticle systems that are stabilized in aqueous environments by surfactants and have a matrix medium composed of solid lipids. Surfactants in the SLNs promote endothelial cell permeability by promoting lipid solubilization and membrane fluidization. Nanoparticles were formulated with six different surfactants and analyzed for particle size (PS) and polydispersity index (PDI), using palmitic acid as the solid lipid for surfactant selection. Pluronic F68 has the smallest PS and PDI, as shown in Figure 1B. Poloxamers are nonionic triblock copolymers made up of a hydrophobic polyoxypropylene chain in the center and two hydrophilic polyoxyethylene chains on either side. Furthermore, poloxamers have been shown to sterically stabilize nanoparticles, inhibit plasma proteins or opsonins from attaching to nanoparticle surfaces, and provide nanoparticles with a hydrophilic characteristic, which can prevent medications containing SLNs from leaving circulation. When compared with single-chain and ionic surfactants, large and nonionic surfactants generally cause less toxicity [17,18]. Because of our previous research on SLNs, we selected soy lecithin as a co-surfactant for this study.

DATS-Lipid-Surfactant Compatibility Analysis
The compatibility of all of the selected ingredients is critical for maximal therapeutic success. The IR spectra ( Figure S1) of DATS exhibited absorption bands at 3086, 2976, and 719 cm −1 , corresponded to the -CH stretching and bending. Palmitic acid's characteristic peaks were -CH stretch at 2915 cm −1 , -OH stretch at 2662 cm −1 , C=O stretch at 1689 cm −1 , and -OH stretch at 937 cm −1 . There were no significant differences in the peak characteristics of DATS and palmitic acid in DATS-SLNs formulated with palmitic acid, confirming that solid lipids and DATS are extremely compatible in formulation conditions.

DoE Approach for the Optimization of DATS-SLNs
There was a substantial shift in PS and % entrapment efficiency (%EE) when the amounts of palmitic acid, Pluronic F68, and soy lecithin were changed. As a consequence, amounts of palmitic acid, Pluronic F68 concentration, and soy lecithin concentration were selected as independent variables for Box-Behnken Design (BBD) optimization of DATS-SLNs. Using the BBD experimental methodology, we optimized the DATS-SLNs formulation by varying the lipid, surfactant, and co-surfactant ratios. The responses recorded for each of the 17 formulations were evaluated for optimization (Table S1). Using perturbation plots and response surface plots, the effects of independent variables on PS and EE were investigated ( Figure 2). An analysis of variance (ANOVA) was used to validate the BBD model (Tables S2 and S3). The optimal formulation was chosen based on the PS (nm) and %EE desirability criteria. The overlay plot of the BBD model of the DATS-SLNs actually demonstrates that 64.15 mg of palmitic acid lipid and 2.23% surfactant along with 0.4% soy lecithin were capable of producing a minimum PS of 108.12 ± 5.45 nm ( Figure S2) (predicted data 106.79 nm) with a %EE of 72.67 ± 4.61% (predicted data 73.21%). The observed findings are in close accord with the design's BBD-model projected values.

Functionalization of Folic Acid to Formulate FA-DATS-SLNs
To increase their target specificity for TNBC, the DATS-SLNs were functionalized with FA to target overexpressed FR. The outer layer that covers the drug-loaded solid lipid core is created by the surfactant and co-surfactant; thus, the surfactant Pluronic F68 was functionalized with FA for target specificity [19].
The -COOH group of the FA is activated by CDI and forms an FA-CDI adduct with an activated carbonyldiimidazole group. The active adduct then reacts with the -OH group of the terminal PEG chain of Pluronic F-68. The molar ratio of FA:CDI:Pluronic F68 was chosen at 1:2:5 to confirm that at least one of the -OH groups of Pluronic F-68 must be conjugated to FA [20]. The conjugation's reaction scheme is depicted in Figure 3A.   Figure S3A). For palmitic acid, the FTIR revealed characteristic peaks of -CH stretch at 2915 cm −1 , -OH stretch at 2662 cm −1 , and C=O stretch at 1689 cm −1 . The FA has two characteristic bands that correspond to the -NH2 group at 3321 cm −1 and 3409 cm −1 .The peak at 1690 cm −1 corresponds to the carboxylic acid group (-COOH). The FTIR spectra of FA-DATS-SLNs exhibited the characteristic peak of FA at 3409 cm −1 in comparison to DATS-SLNs, which indicates the functionalization of the FA on the surface of DATS-SLNs. 1 H NMR validated the synthesis of FA-Pluronic F68. The 1 H NMR spectra of Pluronic F68, FA, and FA-Pluronic F68 are shown in Figure S3B. The typical peaks of PPG in the 1 H NMR spectra of Pluronic F68 ( Figure S3B.a) range from 1.2 ppm to 3.4 ppm, including signal (δ = 1.21 ppm) represent -CH 3 group, signal c (δ = 3.38 ppm) represent -CH 2 group, and signal d (δ = 3.41 ppm) for the -CH group. The polyethylene oxide (PEG) signals (a and b) were the -CH groups with a chemical shift of around 3.4 ppm.
The 1 H NMR spectra of FA was presented in Figure S3B.b. The pteridine proton peaks l (δ = 8.5 ppm), k (δ = 7.6 ppm), aromatic proton peak m (δ= 6.6 ppm), and reactive -COOH peak i (δ = 12.5 ppm) are clearly visible in the FA 1 H NMR spectra. Figure S3B.c illustrates the 1 H NMR spectra of FA-Pluronic F68, which exhibited all of the characteristic signals of Pluronic F68 as well as FA. The signal at I (δ = 12.5 ppm), which corresponds to the FA's -COOH group, does not appear in the spectra of the FA-Pluronic F68 conjugate. The reason for the disappearance of the peak in FA-Pluronic F68 may be due to the chemical reaction between the -COOH of the FA and the -OH of the Pluronic F68. This clearly indicates that the FA was conjugated with the Pluronic F68, which functionalized the FA-DATS-SLNs. The FA conjugation has no influence on the encapsulation of the DATS in the solid core of the SLNs. The FA-DATS-SLNs had an entrapment of 71.91 ± 6.27%, which did not differ substantially from the DATS-SLNs. A difference in PS between the DATS-SLNs and the FA-DATS-SLNs is another evidence of functionalization. The PS of the FA-DATS-SLNs was 168.2 ± 3.78 nm ( Figure S4), which might be attributable to surface functionalization. The increase in PS after FA functionalization might be due to the rearrangement of a shell lipid structure surrounding the core as well as FA conjugation on the surface. A PS with a diameter of less than 200 nm is desirable to penetrate the tumor membrane and gradually accumulate on the target site over time [21]. According to SEM investigations, FA-DATS-SLNs were monodispersed and spherical in form ( Figure 3B). A little rough surface morphology was noticed.
The drug DATS was released from the FA-DATS-SLNs formulation in a controlled yet pH-dependent manner. Both pH 7.4 and pH 5.5 produced an initial burst release of 11% within 2 h. This burst release was caused by the presence of unencapsulated DATS on the SLNs' surface. pH 5.5 mimics the simulated cancer settings, but pH 7.4 is considered a normal physiological pH. The pH-dependent 'off-on' switching of DATS release is triggered by repeated exposure to different release media at pH 7.4 and 5.5 [22]. In changing pH conditions, pH-sensitive FA-Pluronic F-68 regulates DATS release. Furthermore, fatty palmitic acid degrades quickly in an acidic environment compared with pH 7.4 due to protonation of the -COOH group [23]. DATS has a pH-sensitive impact as well. Because of the presence of two sulfide groups, DATS is alkaline in nature and more soluble at lower pH. As a response, the SLN's encapsulated DATS has a high tendency to penetrate the lower pH release medium. A higher rate of DATS release in tumor cells would come from preferential release in an acidic environment. At pH 5.5, about 92.5 ± 4.23% DATS was released after 60 h, whereas only 48.2 ± 8.16% DATS was released at pH 7.4 ( Figure 3C). This suggests that the acidic environment accelerated medication release, which is extremely favorable for TNBC drug delivery.

In Vitro Cytotoxicity Study for Evaluation of Functionalization
Different concentrations of DATS, DATS-SLNs, and FA-DATS-SLNs were studied for cancer cell growth ( Figure 4A) for 48 h. Despite the fact that FR expression is a significant characteristic marker for both MCF-7 and MDA-MB-231 cells, aggressive TNBC is more challenging to target. The Selectivity Index (SI) in Table 1 shows that the cytotoxic effects of DATS, DATS-SLNs, and FA-DATS-SLNs selected for MDA-MB-231 cells indicated greater efficacies for the TNBC. The functionalized FA-DATS-SLNs formulation had a higher SI score of 13.2 for the MDA-MB-231 cell line compared with 8.7 for MCF-7 cancer cell lines.
The cytotoxicity of DATS-SLNs and FA-DATS-SLNs was dose-dependent. When compared with FA-DATS-SLNs, DATS-SLNs showed less cytotoxicity, which may be a result of the drug's efflux into the cytoplasm through P-glycoprotein (P-gp) pumps. FA-DATS-SLNs might enter cells by receptor-mediated endocytosis and have no connection to P-gp efflux. As a result, the drug remains present inside the cells with a high level of cytotoxicity [24,25].    Figure 4B illustrates the long term cytotoxicity efficacy for the MDA-MB-231 cells, with quantitative data presented graphically. FA-DATS-SLNs had fewer colonies than DATS-SLNs (p < 0.01), indicating that functionalized formulations may restrict proliferation, enhance DATS cellular internalization, and inhibit colony formation [26,27] better than DATS and DATS-SLNs over a prolonged period of time.

Cancer Cell Migration Assay
The scratch distance of untreated MDA-MB-231 TNBC cells was lost in less than 8 h. The cell migration assay investigation of DATS-SLNs and FA-DATS-SLNs revealed that DATS-SLNs only prevented cell migration for 36 h, whereas FA functionalization on the surface of DATS-SLNs delayed cell migration until 48 h by promoting higher cellular internalization and more target specificity [28], demonstrating the advanced therapeutic application of the FA-DATS-SLNs over the non-functionalized formulation for TNBC management (Figure 4 C) (p ≤ 0.01 and p ≤ 0.001 under the Student t-test).

DNA Fragmentation Analysis of Functionalization Efficacy for Apoptosis
After 24 h, the DNA was extracted, and the analysis was performed using 1% agarose gel electrophoresis ( Figure 5A). The results clearly showed that MDA-MB-231 cell lines treated with DATS-SLNs and FA-DATS-SLNs exhibited more DNA fragmentation than the marker [21]. Faint fragmentation has also been observed in DATS therapy. The FA-DATS-SLNs may have a superior cellular accumulation of DATS since their concentration is higher due to the formulation being more target-specific. The DATS and the DATS-SLNs need to struggle with the P-gp efflux of the cells and lose therapeutic efficacy in a large manner. FA-DATS-SLNs enter cells by receptor-mediated endocytosis [3,29] and accumulate inside the cells in higher concentrations compared with DATS and DATS-SLNs.

Apoptotic Protein Bcl2 Inhibition Efficacy
Apoptosis inhibition is one of the hallmarks of cancer. Tumor cell death mechanisms include cell cycle arrest, anti-angiogenesis, anti-metastasis, and autophagy, although the great majority of anti-cancer medications have cytotoxic effects on apoptotic signaling pathways in tumors. The apoptosis signaling pathway is regulated by complicated molecular cascade events in the network, which are connected to changes in the expression of certain pro-apoptotic and anti-apoptotic proteins. Pro-apoptotic proteins (Bim, Bax, and Bad) and anti-apoptotic proteins (Bcl2 family proteins) are members of the Bcl2 family (BclxL, Mcl-1, and Bcl2). These proteins are involved in the translocation of mitochondrial mediators as well as in the activation of caspases. Overexpression of the anti-apoptotic protein Bcl2 suppresses apoptosis by blocking mitochondrial outer membrane permeabilization.
Caspase activation (initiator caspase-9 and effector caspase 3) is associated with the mitochondrial mediator cytochrome-C in the intrinsic route. Pro-apoptotic proteins (Bax, Bad, and Bid) and anti-apoptotic proteins (Bax, Bad, and Bid) regulate cytochrome c migration to the cytosol (Bcl2 and BclxL). Caspase-3, a cysteine protease, is triggered by both death receptors and intracellular/mitochondrial apoptotic signals. Caspase-3 deficiency is associated with BC because it is the primary effector protease that causes cell death by cleaving a wide range of death substrates. When compared with DATS-SLNs and free-DATS, FA-DATS-SLNs had higher levels of Bax, Bad, Caspase-9, and Caspase-3 and lower levels of the anti-apoptotic protein Bcl2 ( Figure 5D). This indicates that FA-DATS-SLNs promoted cell death via an intrinsic signaling route.
A Western blot analysis revealed that FA-DATS-SLNs treatment increased the expression of BAX, BAD, Caspase-3, and -9, and decreased the expression of Bcl2 in MDA-MB-231 TNBC cell lines. Western blot analysis strongly demonstrated the protein expression findings of FA-DATS-SLNs at the molecular level. FA-DATS-SLNs in particular demonstrated increased effectiveness through site-specific drug delivery. However, the elevated activity of DATS, which encapsulated SLNs and functionalized them with FA induced a greater apoptotic response. To treat TNBC cells, current chemotherapeutics in clinical and preclinical studies require target-specific administration, which can lessen numerous toxicities and side effects. Overall, FA functionalization on the surface of DATS-SLNs outperformed DATS-SLNs and DATS in terms of targeted and localized action.
Functionalized materials: Folic acid (FA) procured from Sigma-Aldrich, Missouri, USA. All the chemicals are used as procured, without any purification or alteration.

Lipids Selection for FA-DATS-SLNs Formulation
The solubilizing capacity of DATS was estimated by dissolving an extra amount of the drug in 200 mg of lipids (palmitic acid, stearic acid, glyceryl monostearate, glyceryl monooleate, cetyl palmitate, and cholesterol) in a 5 mL stoppered vial, and then the mixture was mixed by a vortex mixer. The sample vials were then kept at 37 ± 2 • C in an isothermal shaker (REMI, Mumbai, India) for 72 h to achieve equilibrium [31]. The dose was increased by 10 mg intervals. The amount of lipids was chosen as the endpoint when no more DATS solubilization was achievable. The equilibrated samples were transferred to a centrifuge tube and rotated at 3500 rpm for 20 min. The supernatant, obtained from the centrifuge, was filtered through a 0.45 µm filter membrane. The amount of DATS was determined by a UV spectrophotometer at 240 nm for each lipid.

Surfactant Selection for FA-DATS-SLNs Formulation
Nanoparticles were formulated with the specified lipid and analyzed for PS, PDI, and entrapment efficiency using various surfactants (such as Pluronic F-68, Pluronic F-127, Pluronic P-85, Tween 20, Tween 60, and Tween 80). The surfactants were chosen based on their PS and PDI [32].

DoE Approach for Optimization of DATS-SLNs
The preliminary screening step in the Design of Experiment (DoE) (V. 7.0, StatEase Inc., Minneapolis, MN, USA) is the most important for choosing crucial formulation parameters and manufacturing qualities that affect critical quality attributes. DATS-SLNs were screened to achieve a minimum PS ≤ 200 nm (particle size influences circulation time, particularly in narrow capillaries where blockage is possible), a narrower PDI value of ≤0.2, and a maximum entrapment efficiency (%EE), (%EE represents the estimated percentage of DATS as the difference between the initial DATS quantity and the unentrapped quantity of DATS in the supernatant with respect to the total amount incorporated in SLNs). Based on the drug's solubilizing capacity in the lipid, the drug-to-lipid ratio and lipids were assessed for optimization [16,33].

•
Optimization of DATS-SLNs using Box-Behnken Design (BBD) Finally, based on early screening data, a three-level, 3 3 design (BBD) was selected for DATS-SLNs optimization [16,33]. The optimization was carried out by analyzing the relationship between dependent variables such as PS, PDI, and %EE and critical manufacturing attributes such as the quantity of palmitic acid, amount of surfactant Pluronic F-68, and concentration of co-surfactant soy lecithin, which were optimized at three levels: high, medium, and low ( Table 2). The variables were optimized using design expert software (Version 11, Stat-Ease Inc., Minneapolis, MN, USA). A total of 17 runs were screened based on the design in order to find the optimized formulation, and the results were documented. Additionally, the DoE generated a polynomial equation to comprehend how factors affected results. In order to compare various statistical parameters, such as the coefficient of variation (CV), multiple correlation coefficient (R 2 ), adjusted multiple correlation coefficient (adjusted R 2 ), predicted residual sum of squares, and graphically by a 3D response surface plot, it was statistically determined which experimental model (linear, two-factor interaction, quadratic, and cubic) fit the data the best. The program suggested the model with the best significance value and highest determination coefficients for the chosen probability. The generated mathematical polynomial equations were then statistically validated using the software's ANOVA (V. 7.0, StatEase Inc., Minneapolis, MN, USA) feature. A p-value of 0.05 or less was considered statistically significant.

• Preparation of DATS-SLN
DATS-SLNs were developed using the hot homogenization process [34]. DATS was dissolved in molten palmitic acid lipid. The hot lipid mixture was dispersed in the hot aqueous phase of surfactant Pluronic F-68 and co-surfactant soy lecithin solution and continuously stirred to produce a coarse o/w emulsion. A high-pressure homogenizer was used to homogenize it at a temperature beyond the lipid's melting point (around 70 • C), producing an oil-water nano-emulsion that was subsequently cooled to room temperature to solidify and create solid lipid nanoparticles. The final formulation was lyophilized and stored for further use.

Functionalization of Folic Acid to Formulate FA-DATS-SLNs
The surfactant Pluronic F68 was functionalized with FA because it forms the outermost layer of the SLNs to create a protective layer for the drug-loaded core. For the FA-Pluronic F68 formulation, 10 mg of FA was thoroughly mixed in 6 mL of dry dimethyl sulfoxide (DMSO). To activate the FA, 20 mg of 1,1-carbonyldiimidazole (CDI) was added to the solution and mixed in the dark overnight [35]. For the synthesis of the FA-Pluronic F68, the FA-activated solution was mixed with 50 mg of dry Pluronic F68 and agitated at room temperature for another 24 h. The purification of the FA-Pluronic F68 was performed by dialyzing (tube: MWCO 3500) the mixture against deionized water for 1 day. The FA-Pluronic F68 was lyophilized and stored at 4 • C. FA-DATS-SLNs were formulated using the same hot homogenization process as DATS-SLNs but using FA-Pluronic F68. The functionalization was confirmed by FT-IR spectroscopy and NMR analysis.
3.2.6. Evaluation of FA-DATS-SLNs -Entrapment Efficiency, Particle Size, Morphology and In Vitro Release Profile The entrapment effectiveness of DATS in the lyophilized SLNs formulation was evaluated using UFLC (SPD-M20A, Shimadzu, Kyoto, Japan) at a λ max of 240 nm. DTAS-SLNs were dissolved in 10 mL of a 1:1 mixture of methanol and sodium dodecyl sulfate during the experiment. The solution was centrifuged for 10 min at 32 • C in a super filter tube using a Sigma-3K30 centrifuge (Sigma-Aldrich, Seelze, Germany). Methanol was used to extract the ultra-filtrate, which was then filtered through a 0.45 µm filter. UFLC [36] was used to analyze the supernatant. The mobile phase was acetonitrile and water (75:25, v/v) with a flow rate of 1.1 mL/min, while the solid phase was a C18 (250 mm 4.6 mm) column. The retention time of the DATS was observed at 9.3 ( Figure S5).
The key function of the SLNs was to increase the DATS therapeutic efficacy and stability while ensuring a minimal PS and a high EE. The Malvern Zeta sizer (Nano ZS, Malvern Instruments, Worcestershire, UK) was used [33] to determine the PS (nm) and ZP (mV) of DATS-SLNs and FA-DATS-SLNs at 25 • C.
SEM images (JEOL JSM 7610F, Tokyo, Japan) were used to investigate the morphology of functionalized FA-DATS-SLNs [33,37]. To make the lipid formulation conductive, it was coated for 3 min with palladium gold (auto fine coater JFC-1600). The picture was captured using a field emission SEM based on the JEOL JSM 7610F (Tokyo, Japan).
The dialysis method was used to evaluate DATS release from the FA-DATS-SLNs formulation at two distinct pH values (5.5 and 7.4) at 37 • C. A total of 1 mg of the lyophilized FA-DATS-SLNs were blended in 1 mL of PBS and put in a dialysis tube (MWCO 8 kDa) (HiMedia, Mumbai, India). The samples were immersed in 3 mL of PBS with agitation at 100 rpm at 37 • C. The samples were collected at 1,4,8,12,24,48, and 72 h intervals while the sink condition was maintained. DATS release was quantified using UFLC at 240 nm. The experiments were carried out in triplicate, and the data were analyzed graphically [33].

•
In vitro cytotoxicity study for evaluation of functionalization The carcinoma cell lines MCF-7 (human breast adenocarcinoma cell line with estrogen, progesterone, and glucocorticoid receptors present), MDA-MB-231 (highly aggressive triple-negative breast cancer (TNBC) cell line that lacks estrogen, progesterone, and human epidermal growth factor receptor), and non-carcinogenic MCF-10A (epithelial cell line isolated from female mammary gland) were used in the FA-DATS-SLNs efficacy experiment. The cytotoxicity of the formulation was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay by the EZ-Cytox Cytotoxicity Assay Kit (DoGen Bio, Seoul, South Korea). The cells were seeded into 96-well plates at a density of 5 × 10 3 cells/well and incubated overnight in Dulbecco's Modified Eagle Medium (DMEM). Next, the medium was removed and cells were washed with 1 mL PBS. Then, the cells were treated with different concentrations (0, 0.625, 1.25, 2.5, 5, and 10 µM in serum-free media) of DATS, DATS-SLNs, and FA-DATS-SLNs and incubated for 48 h at 37 • C under 5% CO 2 conditions. After 48 h, the medium was removed, and the cells were washed with 1 mL of PBS. Following that, 20 µL of MTT solution (stock: 5.0 mg/mL in PBS) from the EZ-Cytox Cytotoxicity Assay Kit [38] was poured into each well. The cells were incubated for 4 h to allow mitochondrial dehydrogenases to activate. Finally, the absorbance of the formazan was measured at 450 nm using a microplate reader (VICTORTM X3, PerkinElmer). The experiment was carried out in triplicate. Untreated control cells exhibited MTT-like cytotoxicity. To compute the concentration of each formulation that reduced growth by 50% and the 95% confidence interval, GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA, USA) software was used to run a nonlinear regression analysis and generate a dose-response curve.
The Selectivity Index (SI) was calculated by dividing the cytotoxicity (IC 50 ) into normal cells (MCF-10A) by the cancer cell cytotoxicity (IC 50 ) (MCF-7 and MDA-MB 231). Treatments with a SI value greater than 3 were shown to be preferentially cytotoxic to MCF-7 and MDA-MB231 cells.

•
Colony formation assay for long term cell cytotoxicity effect of conjugates The clonogenic assay was performed to determine the long-term impact of a cytotoxic substance for 7 days. In the current investigation, the TNBC cell line MDA-MB-231 was plated in triplicate onto 6-well plates at a density of 2000 cells/well. After 24 h, the cells were washed with PBS. DATS, DATS-SLNs, and FA-DATS-SLNs were added to a 37 • C environment with 95% air and 5% CO 2 and incubated for 7 days. On the 7th day, the supernatant was removed and washed with PBS. Methanol and formaldehyde (3:1) were used to fix the cells, and the colonies were stained with 0.5% crystal violet for 15 min. The excess color was washed away with distilled water. The colonies with more than 50 cells were counted using a microscope [39]. The number of colonies was used to calculate cell survival following long-term treatment with the compounds.

•
Cell migration assay Cell migration was studied using a scratch assay. MDA-MB-231 (3 × 10 5 ) was planted in 6 wells. The scratch was formed by scraping with a microtip, and the plates were washed with serum-free media. The cells were cultured for 24 h with DATS-SLNs and FA-DATS-SLNs. The cells were imaged at 0, 24, 36, and 48 h using an Olympus microscope model IX-81 (Tokyo, Japan).

•
DNA fragmentation analysis of functionalization efficacy for apoptosis DNA fragmentation was used as a qualitative marker for cell apoptosis. The DNA ladder was compared with API-treated and control DMSO-treated MDA-MB-231 cells. In a nutshell, 5 × 10 6 cells/mL of cancer cells were transported to a lysis buffer at 65 • C [40]. The cells were treated with 7.1 µg/mL concentration of DATS and an equivalent concentration of DATS in DATS-SLNs and FA-DATS-SLNs formulations. The DNA was extracted using phenol/chloroform/isoamyl-alcohol (25:24:1 v/v), followed by ethanol precipitation after treatment. The DNA was re-suspended in Tris-EDTA buffer, pH 8.0, at 37 • C for 1 h. The extracted DNA was mixed with 1X loading dye and run in triplicate for 15 min on a 2% agarose gel at 50 V. A UV trans-illuminator was used to image the fragmented DNA (Bio-Rad, Hercules, CA, USA).

• TNBC Cellular internalization of functionalized FA-DATS-SLNs
LSCM live cell imaging analyzed the cellular initialization of the FA-DATS-SLNs and DATS-SLNs. In a confocal culture dish, 2 × 10 3 MDA-MB-231 cells were plated and left for incubation overnight. Cells were stained with Nile Red (0.3 µg/mL) at 37 • C for 30 min. Cells were washed three times with PBS and then again stained with ER-Tracker™ Green and DAPI at 37 • C for 30 min. Cells were monitored through the confocal microscope (LSCM, A1Plus, Nikon, Tokyo, Japan) for 2 h to estimate the cellular uptake of DATS-SLNs and FA-DATS-SLNs [41,42]. The image was analyzed by software (NIS-E, Ver.4.00 Nikon).

•
Apoptosis quantification of conjugates efficacy by flow cytometry MDA-MB-231 cells (1 × 10 5 cells/well) were plated in 6-well plates for 24 h. Cells were treated with the 7.1 µg/mL concentration of DATS and the equivalent concentration of DATS in DATS-SLNs and FA-DATS-SLNs formulations. Treated cells were trypsinized, collected, and centrifuged at 15,000 rpm for 3 min. The supernatant was removed, and the cells were washed twice with 1 mL of PBS. Cells were stained with 5 µL of annexin V-FITC and 10µL of Propidium iodide (PI) and incubated for 45 min in dark conditions. The % of annexin-V-positive cells was used to calculate the degree of apoptosis. Flow cytometry analysis of Annexin V/PI-stained cells was provided for cell quantification. Annexin V-negative and PI-negative cells indicate living cells; annexin V-positive but PI-negative cells indicate early apoptotic cells; and annexin V-positive and PI-positive cells indicate late apoptotic and necrotic cells [43].

Conclusions
FA-DATS-SLNs formulated with surface-functionalized FA outperformed non-targeted DATS and DATS-SLNs in terms of cellular absorption, resulting in increased cytotoxicity. FA functionalization boosted target selectivity toward aggressive TNBC MDA-MB-231 cells and has proven to be a successful TNBC therapeutic. FA functionalization successfully overcomes DATS-SLNs' off-targeting limitation. FA-DATS-SLNs were more cytotoxic than DATS and DATS-SLNs, perhaps due to FA ligands' potential to disrupt intrinsic apoptotic signaling pathways. FA-DATS-SLNs significantly downregulate anti-apoptotic proteins (Bcl2) while upregulating pro-apoptotic caspase-9 and enhancing the apoptotic potential of the functionalized formulation by interfering with the intrinsic apoptotic pathway. Thus, the targeting ligand (FA) improved the effectiveness of FA-DATS-SLNs, and this study might open the door for targeted therapy of DATS for the treatment of TNBC using a safe drug delivery vehicle with minimal side effects. However, it should be noted that this is primarily a proof-of-concept study for the construction of FA-functionalized DATS-SLNs for TNBC management. Further in vivo research is needed to assess treatment effectiveness.
Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/molecules28031393/s1, Figure S1: Compatibility study of the lipid palmitic acid with drug DATS in physical mixture as well as in DATS-SLNs formulation; Table S1: BBD model for the DATS-SLNs dependent and independent parameters; Table S2: Analysis of variance (ANOVA) for response surface quadratic model for DATS-SLNs PS; Table S3: Analysis of variance (ANOVA) for response surface quadratic model for DATS-SLNs %EE; Figure S2: Particle size distribution of DATS-SLNs; Figure S3: FTIR conformation of the FA functionalization on the surface of DATS-SLNs; Figure S4: Particle size distribution of FA-DATS-SLNs. Figure